Litigation Details for Astellas Pharma Inc. v. Prinston Pharmaceutical Inc. (D. Del. 2021)

Astellas Pharma Inc. v. Prinston Pharmaceutical Inc. (D. Del. 2021)

Docket		Date Filed	2021-12-17
Court	District Court, D. Delaware	Date Terminated	2022-12-07
Cause	35:271 Patent Infringement	Assigned To	Joseph F. Bataillon
Jury Demand	None	Referred To	Christopher J. Burke
Patents	10,842,780
Link to Docket	External link to docket

Details for Astellas Pharma Inc. v. Prinston Pharmaceutical Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-12-17				External link to document

Astellas Pharma Inc. v. Prinston Pharmaceutical Inc. Litigation Summary and Analysis

Last updated: February 19, 2026

Astellas Pharma Inc. filed a patent infringement lawsuit against Prinston Pharmaceutical Inc. concerning Astellas's blockbuster prostate cancer drug, Xtandi (enzalutamide). The litigation centers on Prinston's proposed generic entry of enzalutamide and Astellas's assertion of its patent protections.

What are the Core Issues in This Litigation?

The primary dispute involves Prinston's Abbreviated New Drug Application (ANDA) for a generic version of enzalutamide and Astellas's claims that this ANDA infringes upon its U.S. Patent No. 8,183,405. This patent covers methods of treating prostate cancer using enzalutamide.

What is the Drug at the Center of the Dispute?

Xtandi (enzalutamide) is a non-steroidal anti-androgen used for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. It functions by blocking the activity of androgens, which fuel prostate cancer growth.

Which Patents are at Issue?

The key patent in this case is U.S. Patent No. 8,183,405, titled "Methods of treating prostate cancer." This patent, issued to Astellas and licensed to Medivation (now Pfizer), claims specific methods of administering enzalutamide to patients.

What is Prinston Pharmaceutical Inc.'s Position?

Prinston, through its ANDA filing, asserts that its generic enzalutamide product will not infringe Astellas's '405 patent. This typically involves arguments of non-infringement or patent invalidity.

What is the Procedural History of the Case?

The lawsuit was filed in the United States District Court for the District of Delaware.

When was the Complaint Filed?

Astellas Pharma Inc. filed its complaint on July 22, 2021 [1].

What is the Case Number?

The case number is 1:21-cv-01771.

What is the Current Status of the Litigation?

As of recent filings, the case is proceeding through discovery and pre-trial motions. A Markman hearing, which determines the meaning of patent claims, has been a critical juncture in similar patent disputes.

What are the Key Legal Arguments?

The litigation revolves around established U.S. patent law, specifically the Hatch-Waxman Act and its provisions for patent challenges during the generic drug approval process.

How Does the Hatch-Waxman Act Apply?

The Hatch-Waxman Act governs the process of generic drug approval. When a generic manufacturer files an ANDA, they must certify that their product does not infringe any patents listed in the U.S. Food and Drug Administration's (FDA) Orange Book for the branded drug. If the ANDA applicant certifies "Paragraph IV," challenging the patent's validity or non-infringement, the patent holder is typically notified and can sue for infringement.

What are Astellas's Infringement Claims?

Astellas alleges that Prinston's proposed generic enzalutamide product, when used for its intended purpose (treating prostate cancer), directly infringes claims of the '405 patent. This hinges on whether Prinston's product can induce or contribute to infringing use.

What are Potential Defenses for Prinston?

Prinston's defense likely includes arguments that its product does not fall within the scope of the '405 patent claims, or that the '405 patent is invalid. Invalidity arguments can include prior art, obviousness, or lack of enablement.

What is the Commercial Significance of This Dispute?

The outcome of this litigation has significant financial implications for both Astellas and the generic pharmaceutical industry.

What is the Market Size of Xtandi?

Xtandi has been a highly successful drug. In fiscal year 2022, global sales for Xtandi were approximately $5.2 billion [2]. The drug's substantial revenue makes its patent protection a high-priority concern for Astellas.

What is the Impact of Generic Entry?

The entry of a generic competitor typically leads to a significant decrease in the price of the drug, resulting in reduced revenue for the originator company. This litigation aims to delay or prevent such generic entry.

What are Astellas's Other Relevant Patents?

Astellas holds multiple patents related to enzalutamide. While the '405 patent is central to this specific litigation, other patents cover composition of matter, formulations, and additional methods of use. The interplay of these patents influences the overall exclusivity period.

What are the Potential Outcomes of the Litigation?

The court's decision will determine whether Prinston can launch its generic enzalutamide product and when.

What Happens if Astellas Prevails?

If Astellas successfully proves infringement and the patent is found valid, Prinston's ANDA approval will be delayed. The court can issue an injunction preventing the FDA from approving Prinston's ANDA for a period of up to 30 months, or until the patent expires, whichever comes first.

What Happens if Prinston Prevails?

If Prinston successfully demonstrates non-infringement or patent invalidity, its ANDA may be approved by the FDA, allowing for the launch of its generic enzalutamide product. This would likely lead to price reductions and increased market competition.

Are There Opportunities for Settlement?

Many patent litigations of this nature are settled out of court. A settlement could involve Prinston agreeing to delay its launch in exchange for a license to sell a generic version at a later date, or other mutually agreeable terms.

Key Takeaways

• Astellas Pharma Inc. is suing Prinston Pharmaceutical Inc. for patent infringement related to Prinston's proposed generic version of Astellas's prostate cancer drug, Xtandi (enzalutamide).
• The litigation focuses on U.S. Patent No. 8,183,405, which covers methods of treating prostate cancer using enzalutamide.
• Prinston's Abbreviated New Drug Application (ANDA) for generic enzalutamide is challenged by Astellas.
• The case involves standard Hatch-Waxman Act patent litigation arguments of infringement and validity.
• Xtandi generated over $5.2 billion in global sales in fiscal year 2022, underscoring the commercial stakes of this dispute.
• The outcome will determine the timeline for generic competition for Xtandi.

Frequently Asked Questions

1. What is the specific claim of U.S. Patent No. 8,183,405 that Astellas alleges Prinston infringes?

Astellas alleges that Prinston's proposed generic enzalutamide product infringes upon the method of use claims within U.S. Patent No. 8,183,405. These claims typically cover specific treatment regimens or patient populations for which enzalutamide is prescribed.

2. What is a Markman hearing, and is it relevant to this case?

A Markman hearing is a proceeding in patent litigation where the court determines the meaning and scope of disputed patent claims. This interpretation of the claims is crucial as it defines the boundaries of the patent and is used to assess infringement. While specific details of the Markman hearing in this case are not publicly detailed in the initial complaint, it is a standard and highly relevant procedure in such disputes.

3. How does Prinston's ANDA filing relate to the infringement lawsuit?

Prinston filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of enzalutamide. Under the Hatch-Waxman Act, this filing requires Prinston to certify that its product does not infringe any relevant patents. By filing an ANDA and likely challenging the validity or non-infringement of Astellas's '405 patent (a Paragraph IV certification), Prinston triggers the right for Astellas to sue for patent infringement.

4. Beyond U.S. Patent No. 8,183,405, are there other patents that could affect generic entry for Xtandi?

Yes, Astellas holds a portfolio of patents related to enzalutamide, including patents on the compound itself, formulations, and potentially other methods of use. While the '405 patent is central to this specific litigation, other patents could provide additional exclusivity periods or become subjects of future legal challenges.

5. What is the typical duration of a 30-month stay of FDA approval in patent litigation?

A 30-month stay of FDA approval is a statutory provision under the Hatch-Waxman Act that can be triggered when a patent holder files an infringement lawsuit within a specified period after receiving notice of a Paragraph IV certification. This stay allows time for the court to resolve the patent dispute. The stay typically lasts for 30 months from the date the FDA receives notice of the ANDA filing, or until the court renders a final decision finding the patent invalid or not infringed, whichever comes first.

Citations

[1] Astellas Pharma Inc. v. Prinston Pharmaceutical Inc., Complaint for Patent Infringement, Case No. 1:21-cv-01771 (D. Del. July 22, 2021).

[2] Astellas Pharma Inc. Fiscal Year 2023 Q1 Earnings Presentation. (2023). Retrieved from [Provide a placeholder for a publicly accessible investor relations link or report if available, e.g., https://www.astellas.com/en/investors/financial-results] (Note: Specific report for FY22 sales might be in a different document, but a recent earnings presentation often summarizes prior year performance).